| For: | Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26 [PMID: 23593532 DOI: 10.4239/wjd.v4.i2.19] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i2/19.htm |
| Number | Citing Articles |
| 1 |
Mehdi Mazloumi, Morteza Entezari, Sanam Samadikhadem, Alireza Ramezani, Homayoun Nikkhah, J. Fernando Arevalo. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS OF RETINAL HYPERPERMEABILITY AND CHOROIDAL INFLAMMATION AS PREDICTORS OF SHORT-TERM FUNCTIONAL AND ANATOMICAL OUTCOMES IN EYES WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL BEVACIZUMAB. Retina 2022; 42(4) doi: 10.1097/IAE.0000000000003361
|
| 2 |
Nurgül Örnek, Mikail Inal, Inci Elif Erbahceci, Tevfik Oğurel, Kemal Örnek. Effect of Intravitreal Bevacizumab on Retrobulbar Blood Flow of Patients with Diabetic Macular Edema. European Journal of Ophthalmology 2015; 25(6) doi: 10.5301/ejo.5000617
|
| 3 |
J Fernando Arevalo, Andres F Lasave, Lihteh Wu, Dhariana Acon, Michel E Farah, Roberto Gallego-Pinazo, Arturo A Alezzandrini, Veronica Fortuna, Hugo Quiroz-Mercado, Guillermo Salcedo-Villanueva, Mauricio Maia, Martin Serrano, Sergio Rojas. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. British Journal of Ophthalmology 2016; 100(12) doi: 10.1136/bjophthalmol-2015-307950
|
| 4 |
Juan S. Peña, François Berthiaume, Maribel Vazquez. Müller Glia Co-Regulate Barrier Permeability with Endothelial Cells in an Vitro Model of Hyperglycemia. International Journal of Molecular Sciences 2024; 25(22) doi: 10.3390/ijms252212271
|
| 5 |
Julio A. Urrets-Zavalía, Evangelina Espósito, Iliana Garay, Rodolfo Monti, Alejandro Ruiz-Lascano, Leandro Correa, Horacio M. Serra, Andrzej Grzybowski. The eye and the skin in endocrine metabolic diseases. Clinics in Dermatology 2016; 34(2) doi: 10.1016/j.clindermatol.2015.12.001
|
| 6 |
Rehan M Hussain, Thomas A. Ciulla. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opinion on Emerging Drugs 2017; 22(3) doi: 10.1080/14728214.2017.1362390
|
| 7 |
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?. EMJ Diabetes 2017; doi: 10.33590/emjdiabet/10313316
|
| 8 |
Alessandro ARRIGO, Emanuela ARAGONA, Francesco BANDELLO. Intravitreal treatments for exudative maculopathies: the efficacy/durability dilemma. Minerva Ophthalmology 2024; 66(1) doi: 10.23736/S2785-1265.23.01881-5
|
| 9 |
Maria Assunta Potenza, Carmela Nacci, Maria Antonietta De Salvia, Luca Sgarra, Massimo Collino, Monica Montagnani. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacological Research 2017; 120 doi: 10.1016/j.phrs.2017.04.009
|
| 10 |
Alessandro Arrigo, Emanuela Aragona, Francesco Bandello. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Annals of Medicine 2022; 54(1) doi: 10.1080/07853890.2022.2064541
|
| 11 |
Lauren M. Ciulla, Nimesh A. Patel, Nicolas A. Yannuzzi, Rehan M. Hussain. Diabetic Eye Disease - From Therapeutic Pipeline to the Real World. 2022; doi: 10.5772/intechopen.99749
|
| 12 |
Rehan M. Hussain, Thomas A. Ciulla. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opinion on Biological Therapy 2016; 16(3) doi: 10.1517/14712598.2016.1131265
|
| 13 |
Joel Hanhart, Itay Chowers. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Reports in Ophthalmology 2015; 6(1) doi: 10.1159/000375230
|
| 14 |
Jiasheng Yang, Guanfang Wang, Xu Xiao, Meihua Bao, Geng Tian, Ali Mohammad Alqudah. Explainable ensemble learning method for OCT detection with transfer learning. PLOS ONE 2024; 19(3) doi: 10.1371/journal.pone.0296175
|
| 15 |
Bogumiła Sędziak-Marcinek, Sławomir Teper, Elżbieta Chełmecka, Adam Wylęgała, Mateusz Marcinek, Mateusz Bas, Edward Wylęgała, Irini Chatziralli. Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence. Journal of Diabetes Research 2021; 2021 doi: 10.1155/2021/6620122
|
| 16 |
Alessandro Arrigo, Francesco Bandello. Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics 2021; 13(7) doi: 10.3390/pharmaceutics13071102
|
| 17 |
Murat Okutucu, Hüseyin Fındık, Mehmet Gökhan Aslan, Medeni Arpa. Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?. BMC Ophthalmology 2021; 21(1) doi: 10.1186/s12886-021-01989-1
|
| 18 |
Francisco Rosa Stefanini, Emmerson Badaró, Paulo Falabella, Michael Koss, Michel Eid Farah, Maurício Maia. Anti-VEGF for the Management of Diabetic Macular Edema. Journal of Immunology Research 2014; 2014 doi: 10.1155/2014/632307
|
| 19 |
Bogumiła Sędziak-Marcinek, Adam Wylęgała, Elżbieta Chełmecka, Edward Wylęgała, Sławomir Teper. How to Achieve Near-Normal Visual Acuity with Bevacizumab in Diabetic Macular Edema Patients. Journal of Clinical Medicine 2021; 10(16) doi: 10.3390/jcm10163572
|
| 20 |
Yi Liu, Qiuyan Zhu, Pengfei Jiang, Yang Yang, Mingyun Wang, Hao Liang, Qinghua Peng, Qiuyan Zhang. Bibliometric and visualized analysis of DME from 2012 to 2022. Medicine 2024; 103(13) doi: 10.1097/MD.0000000000037347
|
| 21 |
Oluwaranti Akiyode, Christine Tran. Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. Diabetes Spectrum 2016; 29(1) doi: 10.2337/diaspect.29.1.44
|
| 22 |
Ramazan Yağcı, Emre Güler. Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy. World Journal of Ophthalmology 2015; 5(3): 133-141 doi: 10.5318/wjo.v5.i3.133
|
| 23 |
Arash Daneshtalab, Meysam Shekofteh, Hesam Fat’hi-zadeh, Mohammad Taher Rajabi, Seyed Mohsen Rafizadeh, Amirhossein Aghajani, Shaghayegh Esfandiarifard, Zahra Akbari, Mahsa Sardarinia, Kaveh Jamalipour Soufi, Amin Zand. Intravitreal Stivant® (a biosimilar to bevacizumab) alone versus combined with triamcinolone in center-involved diabetic macular edema. JFO Open Ophthalmology 2025; 11 doi: 10.1016/j.jfop.2025.100173
|
| 24 |
Martina Tomić, Toma Babić, Tomislav Bulum, Spomenka Ljubić, Tomislav Jukić. Citicoline May Effectively Reduce Hard Exudates in Diabetic Retinopathy. Biomedicines 2025; 13(10) doi: 10.3390/biomedicines13102358
|
| 25 |
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?. EMJ Diabetes 2017; doi: 10.33590/emjdiabet/10314891
|
| 26 |
Zhu-Hong Zhang, Qing-Zhong Chen, Feng Jiang, Todd A. Townsend, Chun-Jie Mao, Cai-Yun You, Wen-Hui Yang, Zhi-Yong Sun, Jin-Guo Yu, Hua Yan. Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy. Molecular Medicine Reports 2017; 15(2) doi: 10.3892/mmr.2016.6048
|
| 27 |
Magdalena Hunt, Sławomir Teper, Adam Wylęgała, Edward Wylęgała, Nikolaos Papanas. Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography. Journal of Diabetes Research 2022; 2022 doi: 10.1155/2022/3547461
|
| 28 |
Huseyin Guzel, Berker Bakbak, Mehmet Talay Koylu, Saban Gonul, Banu Ozturk, Sansal Gedik. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutaneous and Ocular Toxicology 2017; 36(1) doi: 10.3109/15569527.2016.1140177
|